JBM Healthcare issues warning regarding profit growth

Google News

JBM Healthcare issues warning regarding profit growth
Consolidated profit attributable to shareholders is expected to increase by more than 120%

HONG KONG, May 5, 2024 – (ACN Newswire) –JBM (Healthcare) Limited (“JBM Healthcare” or the “Company”, Stock Code: 2161, together with its subsidiaries, the “Group”), a leading branded healthcare product marketing and distribution company in Hong Kong, is a profitable company. announced. . Based on a preliminary review of the Group’s unaudited consolidated management accounts for the year ending 31 March 2024 and information currently available to the Board of Directors of the Company, the Group believes that the increase in consolidated profit was due to the following factors: is expected to be recorded. Shareholder return (“consolidated income”) for the year ended March 31, 2024 increased by more than 120% compared to the same period last year.

The significant increase in consolidated profit was due to the combined effect of improved overall retail market sentiment due to a gradual recovery in tourism to Hong Kong and effective execution of advertising and marketing strategies for leading brands in the proprietary pharmaceutical category . Especially Po Chai Pills and Ho Chai Kung. This encouraging performance confirms the disciplined execution of our growth strategy along offline and online platforms, with positive progress being made in cross-border e-commerce.

JBM Healthcare has a diverse portfolio spanning branded pharmaceuticals, proprietary herbal medicines, and health and wellness products. The Group has implemented strategic initiatives including expanding domestic and cross-border e-commerce platforms, exploring traditional Chinese medicine opportunities for Hong Kong and the Greater Bay Area, adapting product mix to consumer trends and strengthening commercial execution. We continue to advance our strategic priorities. .

Please refer to the Hong Kong Exchange announcement for details.

About JBM (Healthcare) Limited (Security code: 2161)

JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products in Greater China, Southeast Asia, and certain other countries. The Group is a unique field player with marketing expertise and a pharmaceutical tradition that prioritizes product efficacy and quality to meet the healthcare needs of consumers. As a well-known healthcare brand operator in Hong Kong, the Group carries a wide portfolio of branded healthcare products consisting of branded pharmaceuticals, proprietary herbal medicines, and health and wellness products. These products also include well-known household brands such as Po Chai Pills, Ho, etc. Chai Kung Tji Thung San, Contractubex, BITE-X, Mederma for Kids, Tong Tai Chung Woodlock Oil, Flying Eagle Woodlock Oil, Saprintan, Sirin Oil, Consodna Medicinal Oil. JBM Healthcare has been a constituent of the MSCI Hong Kong Microcap Index since May 27, 2021. For more information about JBM Healthcare, please see below.www.jbmhealthcare.com.hk

Topic: Press Release Overview
sauce: JBM (Healthcare) Limited

Sector: Healthcare and Pharmaceuticals
From Asian Corporate News Network

Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Source of this program
“I’m obsessed with plugins, because they’re awesome!”
“HONG KONG, May 5, 2024 – (ACN Newswire) – JBM (Healthcare) Limited (“JBM Healthcare” or the “Company”; stock code: 2161, its subsidiaries, the “Group”) is a leading brand… A healthcare company. product…”
Source: Read more
Source link: https://en.acnnewswire.com/press-release/english/90648/